Entries |
Document | Title | Date |
20080214496 | Use Of Iron(III) Complex Compounds - The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defence and/or brain performance. | 09-04-2008 |
20080214497 | Water dispersible policosanol cyclodextrin complex and method of its production - Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80. | 09-04-2008 |
20080221065 | ORGANIC COMPOUNDS - Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration. | 09-11-2008 |
20080234225 | Method of treatment - A method and composition for preventing the formation of lesions in a patient having a site of inflammation by the use of a cromolyn compound. The cromolyn compound is used with a composition containing penetrating aids. | 09-25-2008 |
20080242636 | MODIFIED CYCLODEXTRIN SULFATE-71 (TERIGYN) AS A MICROBICIDE AGENT - A method of reducing human immunodeficiency virus infective events by applying terygyn and a suitable excipient formulated for topical administration to the vaginal, anal, urethral or penile glans mucosa of an individual prior to or subsequent to infection by human immunodeficiency virus is herein described. | 10-02-2008 |
20080261916 | Synergistic Prebiotic Compositions - The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GF | 10-23-2008 |
20080269167 | Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s) - A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid. | 10-30-2008 |
20080318898 | INCLUSION COMPLEXES OF BUTYLPHTHALIDE WITH CYCLODEXTRIN OR ITS DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THE USE THEREOF - The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others. | 12-25-2008 |
20090005343 | B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN - The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivatives displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity. | 01-01-2009 |
20090012041 | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma. | 01-08-2009 |
20090012042 | Hydroxypropyl-Sulfobutyl-Beta-Cyclodextrin, the Preparation Method, the Analytical Method, and the Pharmacutical Application Thereof - Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree of hydroxypropyl groups; “m” represents the average substituent degree of sulfobutyl groups; “n+m=z” is the gross average substituent degree, in which n is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; m is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; and the gross average substituent degree z is a random integer chosen from 2, 3, 4, 5, 6, 7, 8, 9, 10. The present invention shows low haemolysis and low toxicity. | 01-08-2009 |
20090023682 | Composition Comprising Dietary Fat Complexer and Methods of Using Same - A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the unpleasant gastrointestinal side effects. | 01-22-2009 |
20090023683 | COMPLEXES COMPRISING ZOLEDRONIC ACID AND CYCLODEXTRINS - The present invention relates to stable compositions comprising zoledronic acid, wherein zoledronic acid is complexed with a cyclodextrin, such as hydroxypropyl-β-cyclodextrin. The invention further relates to processes for making the compositions. | 01-22-2009 |
20090036406 | Injection - In the case of storing and supplying an injection containing a 2-[(2-pyridyl)methylsulfinyl]benzimidazole type compound in a plastic container in addition to a glass container, an injection having been improved in stability and solubility and showing excellent qualities without forming any insoluble foreign matters or insoluble microparticles can be obtained by using cyclodextrin or its derivative together. | 02-05-2009 |
20090054375 | Compositions, Systems, and/or Methods Involving Chlorine Dioxide - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. When stored, a concentration of the chlorine dioxide in the composition of matter can be retained, with respect to an initial concentration of chlorine dioxide in said composition of matter, at, for example, greater than 12% for at least 14 days. Certain exemplary embodiments can provide a method comprising releasing chlorine dioxide from a solid composition comprising chlorine dioxide complexed with a cyclodextrin. | 02-26-2009 |
20090111772 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 04-30-2009 |
20090143332 | Cyclodextrin Cyanohydrins - The present invention relates to a compound having a cyclodextrin skeleton wherein a hydrogen atom at the C-6 position in at least one of the sugar moieties has been substituted with a cyano group thereby forming a cyanohydrin-type group. The compounds are found to be excellent catalysts, e.g. for the hydrolysis of aryl glycosides. Accordingly, the compounds of the invention are useful as medicaments, in particular for the treatment of poisoning and drug abuse. The compounds, optionally immobilized to a solid phase material, are useful to reduce the content of harmful substances, e.g. metabolites of fungi, insects, etc., from compositions such as foodstuff. | 06-04-2009 |
20090176737 | Composition for Soft Contact Lens and Adsorption Suppressing Method - Disclosed is a composition for soft contact lenses which enables to suppress adsorption of a basic chemical substance onto a soft contact lens. This composition for soft contact lenses comprises (A) a basic chemical substance selected from amines having a secondary amino group and/or a tertiary amino group and salts thereof, and (B) one or more substances selected from amino acids and salts thereof, acid mucopolysaccharides and salts thereof and cyclodextrin, while having a pH of 3.5 to 4.8. Also disclosed is a method for suppressing adsorption of the basic chemical substance onto a soft contact lens. | 07-09-2009 |
20090239823 | FOODS AND DRINKS HAVING HEALTH BENEFITS AND METHOD FOR ADDING HEALTH BENEFITS TO FOODS AND DRINKS - A method for controlling intestinal function, blood sugar level, body fat or serum lipid, or maintaining and improving glucose tolerance. The method comprises giving to human body or animal foods and drinks, having health benefits, or enriched with health benefits, wherein the foods and drinks comprise as an active ingredient a hydrogenated, indigestible dextrin that is obtained by digesting pyrodextrin with an enzyme to obtain an indigestible dextrin, and then hydrogenating the indigestible dextrin. | 09-24-2009 |
20090270348 | Sulfoalkyl Ether Cyclodextrin Compositions - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD composition comprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. | 10-29-2009 |
20090270349 | Physical Mode of Action Pesticide - A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target. | 10-29-2009 |
20090275530 | Gastric Raft Composition Comprising Preferably Processed Starches For Inducing Satiety - Provided are methods of inducing satiety in an individual using gastric raft compositions and compositions suitable for such methods. The gastric raft compositions may comprise processed starches such as dextrins. Also described are methods of treating diseases characterised by hypoglycaemia, such as glycogen storage disease (GSD), and diabetes. | 11-05-2009 |
20090286757 | Antiviral composition - Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection. | 11-19-2009 |
20090291913 | FACTOR Xa INHIBITOR FORMULATION AND METHOD - An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBE-CD) or hydroxypropyl-β-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome employing the above formulation is also provided. | 11-26-2009 |
20100022474 | Polymer Controlled Induced Viscosity Fiber System and Uses Thereof - The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system. | 01-28-2010 |
20100029585 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE - The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin. | 02-04-2010 |
20100041625 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLODEXTRIN PACLITAXEL INCLUSION AND PREPARATION METHOD THEREOF - A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-β-cyclodextrin, or sulfobutylether-7-β-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M−1−1412M−1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 μm after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion. | 02-18-2010 |
20100048509 | Pharmaceutical Composition Comprising Perindopril - The present invention provides a stable pharmaceutical composition comprising an inclusion complex of perindopril, a microcrystalline cellulose having a low moisture content and/or a silicified microcrystalline cellulose having a low moisture content, and optionally other pharmaceutically acceptable excipients. | 02-25-2010 |
20100056475 | CYCLODEXTRIN CONJUGATES - It has been discovered that the uptake of anionic charged species into cells can be enhanced by noncovalently associating such species with specifically modified forms of cyclodextrin. The invention modified forms of cyclodextrin form well defined stoichiometric complexes with anionic charged molecules. This discovery enables one to produce various compositions containing anionic charged molecules and facilitates methods for enhancing the cellular uptake of double-stranded or hairpin nucleic acid. | 03-04-2010 |
20100056476 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN - The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system. | 03-04-2010 |
20100069327 | NUTRITIONAL PRODUCTS COMPRISING SACCHARIDE OLIGOMERS - Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal. | 03-18-2010 |
20100075923 | METHOD OF ENHANCING TGF-BETA SIGNALLING - The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount. | 03-25-2010 |
20100081631 | METHODS AND COMPOSITIONS FOR TREATING GASTROINTENSTIAL DISORDERS - Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP | 04-01-2010 |
20100087392 | COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS - The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax. | 04-08-2010 |
20100093662 | NOVEL AMPHIPHILIC CYCLODEXTRIN DERIVATIVES - The present invention relates to cyclodextrins having the following formula (I): to nanostructures comprising them, to processes for preparing them, to the use thereof, and also to compositions comprising them. | 04-15-2010 |
20100093663 | Sulfoalkyl Ether Cyclodextrin Compositions - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. | 04-15-2010 |
20100093664 | COMPOSITIONS USEFUL FOR REDUCING NEPHROTOXICITY AND METHODS OF USE THEREOF - The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug. | 04-15-2010 |
20100099647 | Aqueous Iron Carbohydrate Complexes, Their Production And Medicaments Containing Them - Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions. | 04-22-2010 |
20100113387 | FATTY ACIDS FOR USE AS A MEDICAMENT - The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. | 05-06-2010 |
20100113388 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT - An 8-azaprostaglandin represented by formula (I) | 05-06-2010 |
20100130444 | COMPLEXES OF PROSTAGLANDIN DERIVATIVES AND MONOSUBSTITUTED, CHARGED BETA-CYCLODEXTRINS - The present invention relates to water-soluble, non-covalent complexes of a group of prostaglandin derivatives including latanoprost and monosubstituted, charged β-cyclodextrins, as well as uses of these complexes in therapeutic compositions that are administered topically for treating intraocular hypertension and glaucoma. | 05-27-2010 |
20100144670 | Particle Formation - A process for producing particles of a substance is described wherein a solution of the substance in a solvent is delivered in at least one shot into a supercritical fluid. The supercritical fluid is a non-solvent for the substance and is miscible with the solvent. Particles of the substance distributed in a mixture of the solvent and the supercritical fluid are formed. | 06-10-2010 |
20100152134 | EMULSIFIED SKIN EXTERNAL PREPARATION AND METHOD FOR STABILIZING THE SKIN EXTERNAL PREPARATION - An emulsified skin external preparation containing a tocopherol glycinate derivative has excellent storage stability without viscosity reduction during storage. The emulsified skin external preparation includes 0.03 to 25% by mass of a tocopherol glycinate derivative, and 0.05 to 25% by mass of at least one fatty acid ester selected from the group consisting of glycerin mono fatty acid ester, polyglycerin fatty acid ester and dextrin fatty acid ester, the tocopherol glycinate derivative being represented by Formula (1): . . . (1) wherein R | 06-17-2010 |
20100168060 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF - Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided. | 07-01-2010 |
20100173869 | TREATMENT OF SURFACTANTS - The invention relates to a method for treatment of a surfactant, in particular a pulmonary surfactant. The method is further established in that the surfactant is treated with a lipid sequestrating or cholesterol sequestrating surfactant treatment agent, in which given, in particular neutral lipids or cholesterol are selectively sequestrated by means of the surfactant treatment agent, such that the effect of the lipids and/or the effect of the cholesterol on the surfactant is reduced or reversed. | 07-08-2010 |
20100179103 | CURCUMIN CYCLODEXTRIN COMBINATION FOR PREVENTING OR TREATING VARIOUS DISEASES - Curcumin has shown anti-inflammatory and anti-angiogenic properties that could be useful in treating various diseases such as those of rheumatology and oncology. However, curcumin is very poorly absorbed and has a very low bioavailability. This patent describes a method of increasing the delivery of curcumin by complexing it with cyclodextrins. Cyclodextrins are well known in the food industry and have been used to carry other drugs to increase bioavailability. The new combination of cyclodextrins and curcumin has been tested in pre-clinical inflammation models where it has demonstrated efficacy superior to both the positive control and curcumin. | 07-15-2010 |
20100184722 | INCLUSION COMPLEXES OF ALPHA-CYCLODEXTRIN AND SILDENAFIL SALT - Provided are inclusion complexes comprising a sildenafil salt (e.g., sildenafil citrate) and alpha-cyclodextrin. The complexes may be useful treating various conditions, such as male erectile dysfunction and pulmonary hypertension. In some instances the inclusion complexes increase the solubility of sildenafil. Also provided are methods of producing the inclusion complexes, as well as methods of treatment, kits and unit dosages. | 07-22-2010 |
20100204178 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 08-12-2010 |
20100204179 | Resveratrol complex and process for the preperation - The present invention provides products having resveratrol with high water solubility and nutraceutical and/or phytotherapic compositions having said substances. The processes for obtaining them include the solubility increase of the polyphenol corresponding to a resveratrol compound, preferably trans-resveratrol in water, by its complexation with cyclodextrin under specific conditions that favor thermodynamic equilibrium. The products of the invention present high solubility and purity in aqueous medium, being, therefore, useful to prepare nutraceutical compositions (pharmaceutical and/or alimentary) with antioxidant, anti-inflammatory, antiviral, antidiabetics, cardioprotective, neuroprotective, chemoprotective activities; besides protecting against infections and ischemia, reducing obesity, and preventing aging. Phytotherapic compositions useful to the same therapeutical activities, prepared from the complex of resveratrol and cyclodextrin compound, preferably beta-cyclodextrin/trans-resveratrol, are also provided. | 08-12-2010 |
20100234321 | OILY COSMETIC AND COSMETIC PRODUCT - A composition is prepared to comprise (a) 50 to 99% by weight of an oily phase that is a liquid at 25° C., (b) 1 to 7% by weight of dextrin (palmitate/2-ethylhexanoate), and (c) 0.001 to 10% by weight of a coloring material and/or pearlescent agent other than a laminated film powder are contained, followed by making the viscosity thereof at 30° C. when measured with a BL viscometer to be 3,000 to 20,000 mPa·s. In addition, (d) silicic acid anhydride and/or hydrophobized silicic acid anhydride is added thereto. | 09-16-2010 |
20100240606 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE - The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I | 09-23-2010 |
20100240607 | Dextrin-containing composition for preventing surgical adhesions - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin. | 09-23-2010 |
20100261672 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES - A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility. | 10-14-2010 |
20100298265 | Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin - There is described an inclusion complex of raloxifene hydrochloride and β-cyclodextrin in the solid phase having a specific X-ray powder diffraction spectrum. The invention also relates to a process for obtaining the raloxifene hydrochloride inclusion complex with β-cyclodextrin of the invention. The complex of the invention is employed as a pharmaceutical ingredient in the treatment of osteoporosis, specifically postmenopausal osteoporosis. | 11-25-2010 |
20100305063 | Water-Soluble Iron Carbohydrate Derivative Complexes, The Preparation Thereof, And Medicaments Comprising Them - Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivatisation of one or more maltodextrins with an aqueous hypochlorite solution at an alkaline pH value, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of each individual maltodextrin in the mixture is from 2 to 40, and the subsequent derivatisation is carried out with a suitable reagent, process for the preparation thereof, and medicament for the treatment and prophylaxis of iron deficiency states. | 12-02-2010 |
20110009362 | SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided. | 01-13-2011 |
20110021458 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN INCLUSION COMPLEX FORMED BY DISULFIRAM AND A CYCLODEXTRINE, WHICH CAN BE USED IN THE TREATMENT OF ALCOHOL AND COCAINE DEPENDENCE - The invention relates to a novel pharmaceutical composition containing a complex of disulfiram (DSF) with a cyclodextrin (CD), to the method for obtaining same and to the use thereof in the treatment of alcohol and cocaine dependence. | 01-27-2011 |
20110028431 | ORAL MUCOADHESIVE DOSAGE FORM - A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product uniformity may be obtained by complexing the cannabinoid with the cyclodextrin in a liquid medium containing an antioxidant. To enhance stability, product yield and/or product uniformity, complexing may be done while the liquid medium is in contact with an atmosphere having a very low oxygen content. The resulting complexes may be combined with decomplexing agents and/or dispersed in a matrix material comprised of a hydrogel-forming polymer to provide enhanced absorption of the cannabinoid through oral mucosa and reduced ingestion of the cannabinoid as compared with known commercially available cannabinoid-containing oral dosage forms. | 02-03-2011 |
20110028432 | USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma. | 02-03-2011 |
20110034412 | VISUALLY OBSERVABLE MATERIAL FOR MEDICAL TREATMENT - A visually observable material for medical treatment, which is preferable as an adhesion preventive material and a hemostatic material for biological organisms includes a crosslinking composition comprising at least two components of a crosslinking polysaccharide derivative with an active ester group reactive with active hydrogen in the co-presence of an alkali, where the active ester group is preliminarily introduced in a side chain of a polysaccharide and the crosslinking polysaccharide derivative is not yet crosslinked, and a carbonate including at least one type of carbonate generating divalent carbonate ion in an amount at a mass ratio of 0.03 or more to the polysaccharide derivative. | 02-10-2011 |
20110071108 | Beta-Cyclodextrin Derivatives as Antibacterial Agents - The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units. | 03-24-2011 |
20110071109 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTIC AGENTS FOR LYSOSOMAL STORAGE DISORDERS - Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described. | 03-24-2011 |
20110071110 | Water Dispersible Policosanol Cyclodextrin Complex and Method of its Production - Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80. | 03-24-2011 |
20110082105 | COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are compositions comprising a superhydrophilic amphiphilic copolymer and a carrier and composition comprising a superhydrophilic amphiphilic copolymer, a micellar thickener and a carrier. | 04-07-2011 |
20110086815 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES - The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone. | 04-14-2011 |
20110144053 | Process for Obtaining Purified Pterostilbene and Methods of Use Thereof - The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier. | 06-16-2011 |
20110152216 | ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a buffer, excluding phosphate buffer pH 7.0, 0.1M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0. | 06-23-2011 |
20110160159 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 06-30-2011 |
20110172182 | Carboxyethylated Cyclodextrin Polysulfates Useful As Medicaments - This invention relates to novel β-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair. | 07-14-2011 |
20110207697 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS - The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder. | 08-25-2011 |
20110218173 | INCLUSION COMPLEXES OF PINOCEMBRIN WITH CYCLODEXTRIN OR ITS DERIVATIVES - Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs. | 09-08-2011 |
20110224168 | FAT-BINDING COMPOSITIONS - A fat-binding composition contains an inclusion complex with a host molecule and a guest molecule. The guest molecule includes one or more amino acids, vitamins, flavorants or related compounds, rutin, betanin, derivatives thereof, and mixtures thereof. The fat-binding composition may be in the form of a tablet or powder, for example, and may be incorporated into a food or beverage product. If in the form of a powder or tablet, the composition may optionally contain a carbonation-forming component and may be dissolved in carbonated or non-carbonated water. The fat-binding composition may also be employed in a method for binding fat ingested by an animal which includes having the animal ingest the composition, or a food or beverage product containing the same. | 09-15-2011 |
20110237540 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 09-29-2011 |
20110237541 | TRANSDERMALLY ADMINISTERED ALISKIREN - Dosage form of aliskiren, comprising a device for transdermal administration of aliskiren and aliskiren (including salts, prodrugs and metabolites thereof), optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve a desired therapeutic effect. Use of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving a desired therapeutic effect. Method for achieving a desired therapeutic effect by transdermal administration of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s). | 09-29-2011 |
20110245201 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 10-06-2011 |
20110251157 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. | 10-13-2011 |
20110257126 | WATER SOLUBLE CURCUMIN COMPOSITIONS FOR USE IN ANTI-CANCER AND ANTI-INFLAMMATORY THERAPY - The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives. | 10-20-2011 |
20110263528 | ANTIMICROBIAL COMPOSITIONS - This invention provides antimicrobial compositions containing methylglyoxal and material with methylglyoxal contained (such as manuka honey). The antimicrobial activity of methylglyoxal, or material with a methylglyoxal presence, is maintained and/or enhanced by mixing methylglyoxal or material with a methylglyoxal presence with cyclodextrin. Methods of preparing such compositions, including powder composition, and methods of using such compositions are also provided. | 10-27-2011 |
20110275594 | Oral dosage form - A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin. | 11-10-2011 |
20110288049 | Compositions, Systems, and/or Methods Involving Chlorine Dioxide ("ClO2") - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising chlorine dioxide and cyclodextrin, wherein a concentration of chlorine dioxide in the solid complex is greater than 5.8 percent by weight. | 11-24-2011 |
20110312914 | CARBON MONOXIDE REMOVAL AGENT - The present invention provides a carbon monoxide removal agent that can be easily administered to a patient by injection or orally. The carbon monoxide removal agent of the present invention contains, as an active ingredient, an inclusion complex in which a cyclodextrin dimer represented by chemical formula (1) below includes a water-soluble metalloporphyrin. (In the formula, m represents either of number 1 or 2 and n represents any of number 1, 2, or 3.) | 12-22-2011 |
20120004195 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein. | 01-05-2012 |
20120028918 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME - The present invention relates to pharmaceutical compositions that include about 10 mg pazopanib/mL of the composition and about 2 to about 13% w/w of a modified cyclodextrin as well as methods of making the same are described. | 02-02-2012 |
20120035130 | Chirally Correct Retinal Cyclodextrin Acetals for Clarifying Skin Complexion - The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof; | 02-09-2012 |
20120058971 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 03-08-2012 |
20120065161 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-epothilone conjugates are described herein. | 03-15-2012 |
20120077774 | COMPOSITIONS AND THEIR USE FOR REMOVING CHOLESTEROL - The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid. | 03-29-2012 |
20120083467 | DEODORANT COMPOSITIONS - A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. | 04-05-2012 |
20120094954 | COMPOSITIONS COMPRISING AT LEAST ONE COMPLEX COMPOSED OF A DERIVATIVE OF NAPHTHOIC ACID AND OF AT LEAST ONE CYCLODEXTRIN AND USES THEREOF - A composition is described for topical application comprising, in a physiologically acceptable medium, at least one complex composed of a naphthoic acid derivative of formula (I), salts and esters thereof: | 04-19-2012 |
20120115810 | SURGICAL COMPOSITIONS FOR REDUCING THE INCIDENCE OF ADHESIONS - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin. | 05-10-2012 |
20120178711 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 07-12-2012 |
20120196831 | COMPOSITION FOR TREATING AND PREVENTING OBESITY INCLUDING HIGH WATER-SOLUBLE 2-HYDROXYPROPYL-betaCYCLODEXTRIN AS EFFECTIVE COMPONENT - There is provided a composition for preventing and treating obesity including high water-soluble β-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble β-cyclodextrin derivatives, especially, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner. | 08-02-2012 |
20120202772 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein. | 08-09-2012 |
20120202773 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT - A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP | 08-09-2012 |
20120214761 | PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 08-23-2012 |
20120238525 | PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS - Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution. | 09-20-2012 |
20120277184 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES - The invention provides methods for treating, delaying, and preventing pathological conditions caused by pore-forming toxins such as anthrax toxin, α-hemolysin toxin, and ε-toxin using a class of low molecular weight compounds that block the pore formed by these toxins. Specific compounds useful for treating, preventing, or delaying a disease condition caused by | 11-01-2012 |
20120283214 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 11-08-2012 |
20120289479 | Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and Cholesterol - This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream. | 11-15-2012 |
20120289480 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 11-15-2012 |
20120295872 | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma. | 11-22-2012 |
20120309712 | Compositions Comprising Dietary Fat Complexer and Methods for Their Use - This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention. | 12-06-2012 |
20120316133 | AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions. | 12-13-2012 |
20120316134 | ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a bugger, excluding phosphate buffer pH 7.0, 0.1 M mixed as defined in the British Pharmadopoeia 1998, such that the pH of the solution is from 6.0-8.0. | 12-13-2012 |
20130005684 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLODEXTRIN COPOLYMER - The present invention relates to cyclodextrin copolymers, processes for preparing same and their use to prepare pharmaceutical compositions. | 01-03-2013 |
20130029936 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis. | 01-31-2013 |
20130029937 | TREATMENT OF SURFACTANTS - The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation. In the examples we show that MβCD, a cholesterol-sequestrating agent, can restore dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non CF bronchiolitis to normal function. | 01-31-2013 |
20130045947 | PLA2ACTIVITY AS A MARKER FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS - Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA | 02-21-2013 |
20130059816 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 03-07-2013 |
20130059817 | COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT - This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia. | 03-07-2013 |
20130123214 | USE OF DELTA TOCOPHEROL FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS - This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof. | 05-16-2013 |
20130131013 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 05-23-2013 |
20130137657 | QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I): | 05-30-2013 |
20130157975 | AGENT FOR SUPPRESSING ELEVATION OF BLOOD ALCOHOL CONCENTRATION - An object of the present invention is to provide an agent for suppressing elevation of blood alcohol concentration and a method for suppressing elevation of blood alcohol concentration, the agent and the method enabling prevention of an intoxication state upon drinking and further prevention of hepatic dysfunctions due to drinking such as fatty liver. Provided are an agent for suppressing elevation of blood alcohol concentration, comprising a dextrin as an active ingredient, and a method for suppressing elevation of blood alcohol concentration, comprising, when alcohol is ingested, ingesting 0.5 parts by mass or more of a digestible dextrin and/or an indigestible dextrin relative to 1 part by mass of the ingested alcohol. | 06-20-2013 |
20130165405 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 06-27-2013 |
20130172291 | RETINAL CYCLODEXTRIN ACETALS AND HEMIACETALS FOR TREATING SKIN COMPLEXION DISORDER - The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof. | 07-04-2013 |
20130184236 | COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY - Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. | 07-18-2013 |
20130196945 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 08-01-2013 |
20130196946 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 08-01-2013 |
20130196947 | USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD). | 08-01-2013 |
20130196948 | POLYMERS FOR BIOMATERIALS AND THERAPEUTICS - Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally-occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel. In some embodiments, the self-assembled structures may contain an agent, such as a pharmaceutically active agent. Also provided are methods and kits for forming the compositions, methods of using the compositions, and the like. | 08-01-2013 |
20130203700 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 08-08-2013 |
20130244979 | 6-Deoxy-6-Thioether-Amino Acid Cyclodextrin Derivative and Preparation Method Thereof - 6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have a general formula (I). | 09-19-2013 |
20130296268 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL-CYCLODEXTRIN INCLUSION COMPLEX AND ITS PREPARING PROCESS - A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056 M | 11-07-2013 |
20130303482 | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors - This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. | 11-14-2013 |
20130316975 | INCLUSION COMPLEXES CONTAINING PIROXICAM, A CYCLODEXTRIN AND ARGININE - The invention relates to a method for preparing a soluble inclusion complex comprising one or several active substances which are hardly soluble in an aqueous medium and are included in one or several host molecules, using the following successive stages: (a) bringing one or several active substances into contact with one or several host molecules; (b) initiating a molecular diffusion stage by bringing a dense pressurized fluid into contact with the mixture obtained in (a) in a static mode in the presence of one or several diffusing agents; (c) recovering the active substance-host molecule molecular complex formed; (d) adding and mixing an interaction agent with the active substance-host molecule molecular complex; (e) recovering the soluble inclusion compound thus formed. The invention also relates to the soluble inclusion compound obtained by the method, particularly a piroxicam-cyclodextrin-arginine compound. | 11-28-2013 |
20130316976 | PHARMACEUTICAL PREPARATION - The invention relates to a pharmaceutical formulation that contains a complex of a propofol salt with a cyclodextrin. The invention makes it possible to provide propofol in a formulation that can be stored and that can be administered intravenously without problems. | 11-28-2013 |
20130338103 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 12-19-2013 |
20130345169 | Article Suitable for Oral Administration - A material which contains a lipophilic component having a pungent taste or flavor such as a spicy component (e.g., a capsaicin) and a bitter component (e.g., a turmeric extract), in which the pungent taste and/or flavor of the lipophilic component can be reduced effectively, and in which the separation among components contained therein is not caused; a method for producing the material; a composition such as a food, a beverage, a cosmetic and a medicine, which contains the material; and a liquid composition having such a form that the material is dispersed in water. | 12-26-2013 |
20140038918 | TREATMENTS FOR RETINAL DISORDERS - The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy. | 02-06-2014 |
20140066403 | HYDROPHILIC MODIFIED POLYROTAXANE COMPOSITION - The present invention aims to provide a hydrophilic modified polyrotaxane composition having excellent storage stability. The present invention relates to a hydrophilic modified polyrotaxane composition comprising: a hydrophilic modified polyrotaxane produced by modifying, with hydrophilic modifying groups, all or part of hydroxy groups on a cyclodextrin of a polyrotaxane containing the cyclodextrin, a polyethylene glycol which is included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a polyphenol antioxidant. | 03-06-2014 |
20140094432 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES - Processes for precipitating polymers from a polymer-containing solution are disclosed. | 04-03-2014 |
20140094433 | DERMAL FILLER HYDROGELS WITH VITAMIN A/CYCLODEXTRIN INCLUSION COMPLEXES - Compositions, such as hydrogel compositions, that include a hyaluronic acid, a vitamin A, and a cyclodextrin may be used as medical or cosmetic fillers, implants, or creams. For example, the compositions may be used as dermal fillers. | 04-03-2014 |
20140094434 | AMINO ACID COMPOSITION - Amino acid compositions containing a carbohydrate and any one or more kinds of alanine, proline and glycine as amino acid can suppress a rapid increase in the blood glucose level immediately after ingestion and a decrease in the blood glucose level due to prolonged exercise, and can improve exercise performance. In addition, the present invention provides inhibitors of an increase in the blood glucose level immediately after carbohydrate ingestion, an inhibitor of a decrease in the blood glucose level due to a prolonged exercise, and an exercise performance improver. Therefore, the present invention provides an energy supplement useful for those who exercise (particularly prolonged exercise). | 04-03-2014 |
20140107067 | COMPOSITIONS COMPRISING DIETARY FAT COMPLEXERS AND METHODS FOR THEIR USE - This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention. | 04-17-2014 |
20140128343 | COMPLEX OF AMORPHOUS TOMOXIPROLE AND CYCLODEXTRIN WITH FAST DISSOLUTION RATE AND PROCESS FOR THE PREPARATION THEREOF - A stable complex of tomoxiprole with 2-hydroxypropyl-beta-cyclodextrin with fast dissolution rate and rapid absorption wherein amorphous tomoxiprole forms a complex with 2-hydroxypropyl-beta-cyclodextrin in about equimolecular ratio. The complex shows a remarkably faster dissolution rate and absorption with respect to crystalline tomoxiprole and is particularly suitable for the production of pharmaceutical oral dosage forms, such as tablets and capsules, where rapid onset of therapeutical action is required. A method of manufacture of the complex is also described and claimed. | 05-08-2014 |
20140148408 | Antimicrobial Compositions - This invention provides antimicrobial compositions containing methylglyoxal and material with methylglyoxal contained (such as manuka honey). The antimicrobial activity of methylglyoxal, or of material with a methylglyoxal presence, is maintained and/or enhanced by mixing methylglyoxal or material with a methyglyoxal presence with cyclodextrin. Methods of preparing such compositions, including powder composition, and methods of using such compositions are also provided. | 05-29-2014 |
20140155348 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis. | 06-05-2014 |
20140171387 | COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY - Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. | 06-19-2014 |
20140171388 | COMPOUND FOR TREATING CARTILAGE DISORDERS - The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): | 06-19-2014 |
20140187514 | Use Of Iron(III) Complex Compounds - The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defense and/or brain performance. | 07-03-2014 |
20140206643 | PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 07-24-2014 |
20140235574 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD - An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided. | 08-21-2014 |
20140274947 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 09-18-2014 |
20140274948 | RACECADOTRIL LIQUID COMPOSITIONS - A liquid composition comprising racecadotril and cyclodextrin. | 09-18-2014 |
20140274949 | PERSONAL CARE COMPOSITIONS - A composition suitable for topical application, for example, is provided. In some examples, the composition can include particular cyclic oligosaccharides, a fragrance, and a volatile solvent. The compositions disclosed herein may provide a longer lasting fragrance. | 09-18-2014 |
20140288023 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 09-25-2014 |
20140288024 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - Methods and compositions relating to CDP-epothilone conjugates are described herein. | 09-25-2014 |
20140296180 | CYCLIC OLIGOSACCHARIDES FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTION - Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of | 10-02-2014 |
20140336149 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL-CYCLODEXTRIN INCLUSION COMPLEX AND ITS PREPARING PROCESS - A docetaxel inclusion complex having improved water-solubility (up to 5 mg/ml) and stability (stability constant Ka=2056M | 11-13-2014 |
20140364392 | TOPICAL AQUEOUS OPHTHALMIC COMPOSITIONS CONTAINING A 1H-INDOLE-1-CARBOXAMIDE DERIVATIVE AND USE THEREOF FOR TREATMENT OF OPHTHALMIC DISEASE - The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino) methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD). | 12-11-2014 |
20140378414 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein. | 12-25-2014 |
20150018307 | DEODORANT COMPOSITIONS - A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. | 01-15-2015 |
20150025037 | HYPOGLYCEMIC HYPER-BRANCHED MALTODEXTRINS - Hyper-branched maltodextrins having a dextrose equivalent (DE) between at least 8 and at most 15 and a molecular weight or Mw between at least 1,700 and at most 3,000 daltons, characterized in that same have: a 1,6 glucoside bond content between at least 30 and at most 45%; a soluble indigestible fiber content, which is determined according to the AOAC No. 2001-03 method, between at least 75 and at most 100%; and a hypoglycemic capacity expressed according to a test A, which:—in vitro, results in an 80 to 90% reduction of the α-amylase hydrolysis of standard maltodextrins, and—in situ, by a 30 to 45% reduction in the intestinal digestive activity of standard maltodextrins. | 01-22-2015 |
20150065457 | METHOD OF USING CYCLODEXTRIN - Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes. | 03-05-2015 |
20150065458 | Composition for Inactivating an Enveloped Virus - The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus. | 03-05-2015 |
20150119359 | SULFORAPHANE ISOLATION AND PURIFICATION - The present invention relates to methods of isolating and purifying sulforaphane. More specifically, the present invention relates to methods of isolating and purifying sulforaphane from natural sources. The present invention also relates to methods of forming high purity complexes of sulforaphane with cyclodextrin. | 04-30-2015 |
20150296790 | SILICON-CONTAINING COMPOUND AQUEOUS SOLUTION AND ANTIBACTERIAL/ANTIVIRAL AGENT INCLUDING SAID SOLUTION - The present invention may provide an antibacterial and antiviral agent that may include an aqueous solution of a silicon-containing compound that has an antibacterial functional group, the aqueous solution having high stability over time and a strong deodorant effect. | 10-22-2015 |
20150297752 | AQUEOUS ORAL SOLUTIONS OF STEROID HORMONES AND HYDROXYPROPYL-BETA-CYCLODEXTRIN WITH OPTIMISED BIOAVAILABILITY - The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HPβCD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HPβCD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients. | 10-22-2015 |
20150315298 | Cyclodextrin Functionalized Nanoparticles for Quenching Bacterial Communications - A method is generally provided for attaching a polymer chain onto a surface of a nanoparticle, where the polymer chain comprises a cyclic arrangement of saccharides. The resulting grafted nanoparticle is also generally provided, along with its methods of use by exposing to a bacteria colony. | 11-05-2015 |
20150328335 | ARIPIPRAZOLE COMPLEX FORUMLATION AND METHOD - An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided. | 11-19-2015 |
20150352112 | VORICONAZOLE INCLUSION COMPLEXES - The present invention relates to new voriconazole formulations comprising 2-hydroxypropyl-□-cyclodextrins and the preparation thereof. | 12-10-2015 |
20150359757 | A METHOD FOR IMPROVING THE WELLBEING OF AN ANIMAL USING A COMPOSITION INCLUDING VITAMIN K - There is disclosed herein a method of improving the wellbeing, as herein defined, of an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent. | 12-17-2015 |
20160008358 | STABLE PHARMACEUTICAL INJECTABLE COMPOSITIONS OF VORICONAZOLE | 01-14-2016 |
20160025712 | COMPOSITIONS AND METHODS FOR PREDICTING AGE OF ONSET OF A LYSOSOMAL STORAGE DISEASE OR A DISEASE ASSOCIATED WITH A LYSOSOMAL DEFECT - The present invention features diagnostic compositions and methods for predicting the age of onset of a lysosomal storage disease or a disease associated with a lysosomal defect in subject. | 01-28-2016 |
20160046569 | N-HYDROXYMETHANESULFONAMIDE NITROXYL DONORS - The disclosed subject matter provides N-hydroxymethanesulfonamide compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. | 02-18-2016 |
20160051574 | COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT - This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia. | 02-25-2016 |
20160058786 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 03-03-2016 |
20160082111 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 03-24-2016 |
20160106717 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS - This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid. | 04-21-2016 |
20160106718 | CAI-BASED SYSTEMS AND METHODS FOR THE LOCALIZED TREATMENT OF UVEITIS - This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid. | 04-21-2016 |
20160143918 | DRUG RELEASING AGENT BASED ON beta-SITOSTEROL AND A PREPARATION METHOD THEREOF - The present invention relates to the technical field of β-sitosterol drugs and provides a drug sustained release agent based on β-sitosterol and a preparation method thereof. The drug sustained release agent based on the β-sitosterol is applied to drugs with the β-sitosterol as a main drug component and is prepared from the components including a drug carrier, a hydrophilic gel material, a erodible matrix material and an insoluble matrix material, wherein the drug carrier is a β-cyclodextrin-polyamide-amine dendrimer composites, β-sitosterol is from a plant raw material, and a host-guest inclusion complex is composed of the main drug component and the drug carrier according to the mass ratio of 0.1:0.1-0.1:5. A preparation method comprises the following steps: preparing the inclusion complex, mixing auxiliaries, carrying out compression moulding and the like. The drug sustained release agent based on β-sitosterol has the characteristics of stable drug concentration, high biological activity, good drug solubility and long acting effect. | 05-26-2016 |
20160143942 | COMPOSITIONS AND THEIR USE FOR REMOVING CHOLESTEROL - The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid. | 05-26-2016 |
20160166567 | TREATMENT OF CANCER | 06-16-2016 |
20160199512 | POLYROTAXANE AND MEDICINAL COMPOSITION | 07-14-2016 |
20160251320 | Compounds | 09-01-2016 |
20170231258 | RICE COOKING METHOD AND COOKED RICE | 08-17-2017 |
20180021367 | USE OF A MIXTURE OF MODIFIED GLUCOSE POLYMERS FOR REDUCING TUMOR METASTASIS | 01-25-2018 |
20180022901 | FAT-BINDING COMPOSITIONS | 01-25-2018 |